States Restrict HIV Drug Access as Federal Funds Stagnate and Costs Rise

Across the nation, a severe funding shortfall is forcing states to make agonizing decisions that directly threaten the health of thousands of Americans living with HIV. At the heart of the crisis is the AIDS Drug Assistance Program (ADAP), a crucial safety net funded by the Ryan White HIV/AIDS Program.

For over a decade, federal funding for ADAP has remained entirely stagnant at $900.3 million since fiscal year 2014. When adjusted for inflation, the program currently has the same purchasing power it did in 1999. Meanwhile, the financial pressures on the program have skyrocketed: client enrollment jumped 56% between 2007 and 2024, the costs of prescription drugs have soared, and insurance premiums have increased significantly. Consequently, more than 20 states are now actively reducing or considering cutting back on their ADAP funding.

Nowhere is this crisis more acute than in Florida. Utilizing an "11th hour" emergency rule just a day before a major lawsuit hearing, the Florida Department of Health abruptly cut off approximately 12,000 people from receiving affordable HIV medication. The state drastically reduced the program's income eligibility limit from 400% of the federal poverty level (roughly $60,000 a year) to just 130% (about $21,000 annually). Furthermore, Florida is removing Biktarvy—the most widely prescribed antiretroviral medication in the U.S.—from its formulary and rolling back its insurance assistance program.

Advocates are outraged. The AIDS Healthcare Foundation (AHF) is actively suing the state, calling the sudden, emergency-rule policy change "legal subterfuge". State politicians and longtime advocates alike warn of the panic and fear spreading among patients who suddenly find themselves without access to life-saving care.

Florida is not alone in its struggles. States like Pennsylvania, Kansas, Delaware, and Rhode Island have also reduced income eligibility for their programs. Desperate measures not seen in over a decade, such as patient waitlists, are now being considered by states like Arkansas, Louisiana, and New Jersey.

Experts are sounding the alarm. Ultimately, these severe rollbacks in HIV drug access threaten to reverse decades of public health progress, risking worsened health outcomes, increased mortality, and a tragic spike in new HIV infections.

---

🔖 Sources

States roll back HIV drug access as federal funds stagnate 

Constrained Budgets Lead States to Restrict HIV Drug Access Through Ryan White

Florida suddenly cuts off 12,000 people from receiving their HIV meds

---

Keywords: HIV Drug Access

HIV Drug Access

---